News & Analysis

Johnson & Johnson results beat estimates

20 July 2022 By Klavs Valters


Johnson & Johnson (JNJ) reported its latest financial results for the second quarter before the opening bell in the US on Tuesday.

The US pharmaceutical and consumer goods company reported revenue that topped the Wall Street expectations at $24.02 billion (up 3% year-over-year) vs. $23.771 billion expected.

Earnings per share reported at $2.59 per share (up 4.4% year-over-year) vs. $2.54 per share estimate.

”Our solid second quarter results across Johnson & Johnson reflect the strength and resilience of our Company’s market leadership in the midst of macroeconomic challenges,” said Joaquin Duato, CEO of the company.

”I am continually energized by the focus and passion of my Johnson & Johnson colleagues and their dedication toward delivering transformative healthcare solutions to patients and consumers around the world,” Duato concluded.

Johnson & Johnson (JNJ) chart

The stock was down by around 1% during the trading day on Tuesday at $172.37 per share.

Here is how the stock has performed in the past year:

  • 1 Month -0.31%
  • 3 Month -5.79%
  • Year-to-date +0.82%
  • 1 Year +2.39%

Johnson & Johnson price targets

  • Wells Fargo $195
  • Morgan Stanley $174
  • Citigroup $205
  • Raymond James $196
  • Credit Suisse $205
  • Goldman Sachs $181

Johnson & Johnson is the 10th largest company in the world with a market cap of $453.99 billion.

You can trade Johnson & Johnson (JNJ) and many other stocks from the NYSE, NASDAQ, HKEX and the ASX with GO Markets as a Share CFD.

Sources: Johnson & Johnson, TradingView, MetaTrader 5, Benzinga, CompaniesMarketCap

Ready to start trading?

Disclaimer: Articles are from GO Markets analysts and contributors and are based on their independent analysis or personal experiences. Views, opinions or trading styles expressed are their own, and should not be taken as either representative of or shared by GO Markets. Advice, if any, is of a ‘general’ nature and not based on your personal objectives, financial situation or needs. Consider how appropriate the advice, if any, is to your objectives, financial situation and needs, before acting on the advice. If the advice relates to acquiring a particular financial product, you should obtain and consider the Product Disclosure Statement (PDS) and Financial Services Guide (FSG) for that product before making any decisions.